Financial Performance - During the Reporting Period, the company recorded revenue of RMB75.0 million from Airdoc Eye Health, representing a year-over-year increase of 113.5% in the number of service sites covered, reaching 1,986[15]. - Revenue increased by 79.5% from RMB113.7 million in 2022 to RMB204.0 million in 2023, driven by a 200.0% increase in Airdoc Medical and a 71.9% growth in Airdoc Eye Health[48]. - The company recorded a loss of RMB145.7 million for the year ended December 31, 2023, a 20.3% reduction compared to a loss of RMB182.7 million in 2022[29]. - The gross profit for 2023 was RMB 125,133,000, compared to RMB 55,852,000 in 2022, indicating a growth of approximately 124.4%[196]. - The company reported a loss before tax of RMB 145,859,000 in 2023, an improvement from a loss of RMB 182,740,000 in 2022, narrowing the loss by approximately 20.2%[196]. Research and Development - The company was granted 87 new patents during the Reporting Period, bringing the total to 230 patents, including 108 inventions[7]. - R&D expenses decreased by 11.1% from RMB125.6 million in 2022 to RMB111.6 million in 2023, primarily due to a reduction in share-based payments[24]. - The company plans to continue investing in R&D and accelerate product innovation to lead high-quality development with technology[179]. Sales and Marketing - The company has developed a flexible and multi-channel sales and marketing strategy to cover various commercialization pathways in healthcare settings[8]. - The company’s AI-based software solutions generated significant revenue from medical institutions, including hospitals and community clinics, alongside hardware sales[20]. - The company is focused on expanding its market coverage beyond clinical departments to primary healthcare institutions and consumer health environments[183]. Corporate Governance - The Company has adopted the Corporate Governance Code to enhance management and protect shareholder interests[79]. - The Board consists of four executive Directors, including Mr. Zhang, and three independent non-executive Directors, ensuring a strong independent element in its composition[80]. - The Company emphasizes the importance of good corporate governance to enhance management and protect overall shareholder interests[79]. Product Development and Innovation - Airdoc achieved significant progress in product development, with Airdoc-AIFUNDUS (1.0) receiving certification under the European Union Medical Device Regulation (CE MDR)[148]. - The AI-FUNDUSCAMERA-P and myopia treatment products received international gold awards, recognizing the company's technological innovation capabilities[148]. - The proprietary AI-empowered retina-based deep algorithm platform positions the company as a leader in early detection and diagnosis solutions in China[183]. Market Expansion and Customer Engagement - The company provided services to 6.83 million patients, identifying 31,459 significant positive cases through AI retinal monitoring, contributing to early detection of severe conditions[178]. - The company aims to address the needs for eye health evaluation and myopia control, particularly for the younger generation, through its Airdoc Eye Health solutions[15]. - The company’s brand is highly regarded by medical experts, contributing to its growth in customer numbers and unit prices in 2023[199]. Financial Position - As of December 31, 2023, the company's current assets were RMB1,281.9 million, including cash and cash equivalents of RMB891.5 million[61]. - Current liabilities as of December 31, 2023, amounted to RMB110.2 million, with trade payables of RMB17.5 million and contract liabilities of RMB23.7 million[61]. - Non-current assets increased significantly to RMB 402,985,000 in 2023 from RMB 64,137,000 in 2022, reflecting a growth of approximately 528.5%[196].
鹰瞳科技-B(02251) - 2023 - 年度财报